Clinical Trials Logo

Arthritis, Psoriatic clinical trials

View clinical trials related to Arthritis, Psoriatic.

Filter by:

NCT ID: NCT02164214 Completed - Clinical trials for Rheumatoid Arthritis

Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)?

Start date: September 2011
Phase: Phase 3
Study type: Interventional

TWEAK (TNF weakly inducer of apoptosis) is a type II-transmembrane protein, member of the TNF ligand superfamily that can be cleaved to function as a soluble cytokine. Depending on target cell type, TWEAK triggers multiple cellular responses ranging from modulation of inflammation to cell death when it binds to its main receptor, Fn 14. Our team has been the first to describe pro-inflammatory effects of TWEAK during central nervous system inflammation. Various data support the possibility that TWEAK produced by synovial macrophages may contribute to chronic synovitis in animal models and in humans. In psoriatic arthritis (PsoA), anti-TNF therapy has been successful concording with the key role of TNF in the pathogenesis of this disease and the generation by psoriatic patients of neutralizing anti-TNF autoantibodies referred as "beneficial autoimmunity to pro-inflammatory mediators". In 2010, Van Kuijk et al. have described a high expression of TWEAK in the inflammatory synovial of PsoA and rheumatoid arthritis (RA) patients before and after anti-TNF therapy. The role of TNF-alpha in the regulation of TWEAK expression remains unclear.

NCT ID: NCT02154425 Completed - Clinical trials for Rheumatoid Arthritis

A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers

CRADLE
Start date: September 2014
Phase: Phase 1
Study type: Interventional

The primary objectives of this study are to assess whether there is transfer of Certolizumab Pegol (CZP) into breast milk of lactating mothers who are receiving an established dosing regimen of CZP by evaluating the concentration of CZP in mature breast milk, and to calculate the daily infant dose of maternal CZP.

NCT ID: NCT02148640 Completed - Clinical trials for Rheumatoid Arthritis

The NOR-SWITCH Study

NOR-SWITCH
Start date: October 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of switching from Remicade to the biosimilar treatment Remsima in patients with rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease and chronic plaque psoriasis

NCT ID: NCT02141763 Completed - Psoriatic Arthritis Clinical Trials

Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis

Start date: May 2014
Phase: Phase 1
Study type: Interventional

A study of UCB4940 in subjects with psoriatic arthritis to evaluate the safety and body distribution of UCB4940 in those patients. Neither the patient nor the doctor will know the treatment group.

NCT ID: NCT02098694 Completed - Clinical trials for Arthritis, Psoriatic

Physiotherapy-led Outpatient Clinic for Patients With Spondyloarthritis

Start date: June 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether patients with spondyloarthritis are more satisfied with a physiotherapy-led outpatient clinic than usual care and whether there is a difference between patients in a physiotherapy-led outpatient clinic and those in usual care regarding disease activity, function and mobility.

NCT ID: NCT02065713 Completed - Psoriatic Arthritis Clinical Trials

Efficacy of Golimumab in Combination With Methotrexate (MTX) Versus MTX Monotherapy, in Improving Dactylitis, in MTX naïve Psoriatic Arthritis Patients

GO-DACT
Start date: August 2014
Phase: Phase 3
Study type: Interventional

Dactylitis is a poor prognostic factor in psoriatic arthritis (PsA) patients. The efficacy of synthetic or biologic disease modifying anti-rheumatic drugs (DMARDs) on dactylitis has not been previously studied in randomized controlled trials as a primary endpoint. In this investigator initiated clinical trial the investigators aim to test the hypothesis that the combination therapy of golimumab and methotrexate (MTX) will result in a significant improvement of dactylitis in comparison with MTX monotherapy, in MTX naïve psoriatic arthritis patients, at week 24. Similarly the efficacy on enthesitis, peripheral and axial involvement, skin and nail psoriasis, inflammation and damage of the feet and hands assessed by magnetic resonance imaging (MRI), composite indexes of disease activity, remission, function and quality of life will be determined. This is a national multicentre, interventional, double-blinded, placebo-controlled, parallel design trial. 136 patients with active dactylitis, refractory to at least two systemic non-steroidal anti-inflammatory drugs (NSAIDs), at optimal dosage, for 3 months will be included and centrally randomized to golimumab in combination with MTX versus MTX monotherapy, in a 1:1 ratio. The study duration will be 24 weeks. The investigators expect the results from this trial will contribute to a better definition of the treatment algorithm of PsA patients with dactylitis.

NCT ID: NCT02052609 Completed - Psoriatic Arthritis Clinical Trials

A Phase 3 Clinical Study of KHK 4827

Start date: February 2014
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the safety and efficacy of long-term exposure to KHK4827 in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic erythroderma) who have completed Study 4827-003 (Study 003)and in subjects with pustular psoriasis (generalized) or psoriatic erythroderma who have completed the Study 4827-004 (Study 004).

NCT ID: NCT02028169 Completed - Psoriatic Arthritis Clinical Trials

To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis

PsA
Start date: January 2014
Phase: N/A
Study type: Observational

This post marketing observational study (PMOS) is designed to provide the initial data on work impairment of Psoriatic Arthritis (PsA) patients in Turkey, as well as changes in work impairment, life quality and clinical response during treatment with anti-TNF agents.

NCT ID: NCT02024646 Completed - Psoriatic Arthritis Clinical Trials

Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis

AMVISION-2
Start date: March 2014
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis. The key secondary objective is to evaluate the efficacy of brodalumab compared to placebo at week 16. The safety objective of this study is to evaluate the safety profile of brodalumab in subjects with psoriatic arthritis.

NCT ID: NCT02019602 Completed - Clinical trials for Rheumatoid Arthritis

A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta

CRIB
Start date: January 2014
Phase: Phase 1
Study type: Interventional

The primary purpose is to assess whether there is transfer of Certolizumab Pegol (CZP) from pregnant women receiving treatment with Cimzia® across the placenta to infants by evaluating the concentration of CZP in the plasma of infants at birth.